











Amendment to the Claims. Please amend claims 2, 3, 6, 7, 9, 10, 12-15, 17 and 18; add new claims 19-29 and cancel claims 1, 4 and 5 without prejudice as follows:









Listing of the Claims. This listing replaces any previous listing.







1 (Cancelled).


2 (Currently amended). A method for treating familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy, in a subject, comprising administering, to the subject, a compound represented by a structural formula ~~The method of claim 1 wherein the compound of Formula A comprises a formula~~ selected from the group consisting of:














(-) - enantiomer




(+) - enantiomer




(-) - enantiomer











(+) - enantiomer




(-) - enantiomer




(-) - enantiomer







(+) - enantiomer




(-) - enantiomer





(+) - enantiomer




(-) - enantiomer




(+)-enantiomer







;




;




;




;




;











;
















;




;












;





;




;




;



; and



3 (Currently amended). A method for treating ~~or preventing a~~
~~disorder of calcium homeostasis~~ familial benign hypocalciuric
hypercalcemia, neonatal severe primary hyperparathyroidism,
renal secondary hyperparathyroidism, osteoporosis, malignancy-
associated hypercalcemia or humoral hypercalcemia of
malignancy, in a subject, comprising administering, to the
 subject, a compound ~~according to~~ represented by the following
structural formula:



4 (Cancelled).

5 (Cancelled).

6 (Currently amended). The method of claim ~~1~~ 2 wherein the subject is a human, a dog or a cat.

7 (Currently amended). The method of claim ~~1~~ 2 wherein the compound is administered in combination with a pharmaceutically acceptable carrier in a pharmaceutical composition.

8 (Original). The method of claim 7 wherein the pharmaceutical composition is in the form of a pill, tablet or capsule.

9 (Currently amended). The method of claim ~~1~~ 2 wherein ~~the a~~ a compound represented by a structural formula selected from the group consisting of ~~Formula A~~ Formulas 1-81 is administered in association with a second compound for treating ~~a disorder of calcium homeostasis~~ familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy.

10 (Currently amended). The method of claim 9 wherein the second compound is selected from the group consisting of AMG073, NPS467, NPS568, gadolinium, lanthanum, neomycin, Mg²⁺, 1,25-dihydroxyvitamin D, calcitrol, paricalcitrol, doxercalciferol, zoledronic acid, calcitonin, alfacalcidol and oxacalcitriol.

11 (Original). The method of claim 9 wherein the second compound is administered in combination with a pharmaceutically acceptable carrier in a pharmaceutical composition.

12 (Currently amended). The method of claim 11 wherein said compound represented by a structural formula selected from the group consisting of Formulas 1-81; ~~of Formula A~~ and said second compound are administered in combination with a pharmaceutically acceptable carrier in a single pharmaceutical composition.


13 (Currently amended). The method of claim 11 wherein said compound represented by a structural formula selected from the group consisting of ~~Formula A~~ Formulas 1-81 and said second compound are administered in combination with pharmaceutically acceptable carriers in two separate pharmaceutical compositions.

14 (Currently amended). The method of claim 13 wherein said compound represented by a structural formula selected from the group consisting of ~~Formula A~~ Formulas 1-81 and said second compound are administered simultaneously.

15 (Currently amended). The method of claim 13 wherein said compound represented by a structural formula selected from the group consisting of ~~Formula A~~ Formulas 1-81 and said second compound are administered non-simultaneously.

16 (Original). The method of claim 11 wherein the pharmaceutical composition is in the form of a pill, tablet or capsule.

17 (Currently amended). A The method of claim 2 wherein the
~~for decreasing the level of Ca^{2+} , parathyroid hormone or~~
~~parathyroid hormone related protein in the serum of a said~~
~~subject decreases following said administration comprising~~
~~administering a compound according to the following formula to~~
~~the subject.~~




~~wherein R1 can be hydrogen or halogen~~



~~R2, R3 and R4 are independently selected from H and halogen~~
~~provided that at least one of R2, R3 and R4 is H;~~

~~— represents an optional bond;~~

~~R5 represents C when the optional bond to R5 is present and~~
~~represents CH or N when the optional bond to R5 is absent; and~~
~~R6 is selected from~~



18 (Currently amended). A method for treating familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy ~~or preventing a disorder of calcium homeostasis~~ , in a subject, comprising administering, to the subject, a compound represented by ~~according to~~ the following structural formula:



19 (New). The method of claim 3 wherein the subject is a human, a dog or a cat.

20 (New). The method of claim 3 wherein the compound represented by structural formula 1 is administered in combination with a pharmaceutically acceptable carrier in a pharmaceutical composition.

21 (New). The method of claim 20 wherein the pharmaceutical composition is in the form of a pill, tablet or capsule.

22 (New). The method of claim 3 wherein the compound represented by structural formula 1 is administered in association with a second compound for treating familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy.

23 (New). The method of claim 22 wherein the second compound is selected from the group consisting of AMG073, NPS467, NPS568, gadolinium, lanthanum, neomycin, Mg^{2+} , 1,25-dihydroxyvitamin D, calcitrol, paricalcitol, doxercalciferol, zoledronic acid, calcitonin, alfacalcidol and oxacalcitriol.

24 (New). The method of claim 22 wherein the second compound is administered in combination with a pharmaceutically acceptable carrier in a pharmaceutical composition.

25 (New). The method of claim 22 wherein said compound represented by structural formula 1 and said second compound are administered in combination with a pharmaceutically acceptable carrier in a single pharmaceutical composition.

26 (New). The method of claim 22 wherein said compound represented by structural formula 1 and said second compound are administered in combination with pharmaceutically acceptable carriers in separate pharmaceutical compositions.

27 (New). The method of claim 22 wherein said compound represented by structural formula 1 and said second compound are administered simultaneously.

28 (New). The method of claim 22 wherein said compound represented by structural formula 1 and said second compound are administered non-simultaneously.

29 (New). The method of claim 24 wherein the pharmaceutical composition is in the form of a pill, tablet or capsule.